Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 31

1.

The National Cancer Institute ALMANAC: A Comprehensive Screening Resource for the Detection of Anticancer Drug Pairs with Enhanced Therapeutic Activity.

Holbeck SL, Camalier R, Crowell JA, Govindharajulu JP, Hollingshead M, Anderson LW, Polley E, Rubinstein L, Srivastava A, Wilsker D, Collins JM, Doroshow JH.

Cancer Res. 2017 Jul 1;77(13):3564-3576. doi: 10.1158/0008-5472.CAN-17-0489. Epub 2017 Apr 26.

2.

Phosphorylated fraction of H2AX as a measurement for DNA damage in cancer cells and potential applications of a novel assay.

Ji J, Zhang Y, Redon CE, Reinhold WC, Chen AP, Fogli LK, Holbeck SL, Parchment RE, Hollingshead M, Tomaszewski JE, Dudon Q, Pommier Y, Doroshow JH, Bonner WM.

PLoS One. 2017 Feb 3;12(2):e0171582. doi: 10.1371/journal.pone.0171582. eCollection 2017.

3.

An in silico screen links gene expression signatures to drug response in glioblastoma stem cells.

Riddick G, Song H, Holbeck SL, Kopp W, Walling J, Ahn S, Zhang W, Fine HA.

Pharmacogenomics J. 2015 Aug;15(4):347-53. doi: 10.1038/tpj.2014.61. Epub 2014 Dec 2.

PMID:
25446780
4.

Gene expression profiling of 49 human tumor xenografts from in vitro culture through multiple in vivo passages--strategies for data mining in support of therapeutic studies.

Hollingshead MG, Stockwin LH, Alcoser SY, Newton DL, Orsburn BC, Bonomi CA, Borgel SD, Divelbiss R, Dougherty KM, Hager EJ, Holbeck SL, Kaur G, Kimmel DJ, Kunkel MW, Millione A, Mullendore ME, Stotler H, Collins J.

BMC Genomics. 2014 May 22;15:393. doi: 10.1186/1471-2164-15-393.

5.

The exomes of the NCI-60 panel: a genomic resource for cancer biology and systems pharmacology.

Abaan OD, Polley EC, Davis SR, Zhu YJ, Bilke S, Walker RL, Pineda M, Gindin Y, Jiang Y, Reinhold WC, Holbeck SL, Simon RM, Doroshow JH, Pommier Y, Meltzer PS.

Cancer Res. 2013 Jul 15;73(14):4372-82. doi: 10.1158/0008-5472.CAN-12-3342. Epub 2013 Jul 15.

6.

Downregulation of Pdcd4 by mir-21 facilitates glioblastoma proliferation in vivo.

Gaur AB, Holbeck SL, Colburn NH, Israel MA.

Neuro Oncol. 2011 Jun;13(6):580-90. doi: 10.1093/neuonc/nor033.

7.

Analysis of Food and Drug Administration-approved anticancer agents in the NCI60 panel of human tumor cell lines.

Holbeck SL, Collins JM, Doroshow JH.

Mol Cancer Ther. 2010 May;9(5):1451-60. doi: 10.1158/1535-7163.MCT-10-0106. Epub 2010 May 4.

8.

Bisindenoisoquinoline bis-1,3-{(5,6-dihydro-5,11-diketo-11H-indeno[1,2-c]isoquinoline)-6-propylamino}propane bis(trifluoroacetate) (NSC 727357), a DNA intercalator and topoisomerase inhibitor with antitumor activity.

Antony S, Agama KK, Miao ZH, Hollingshead M, Holbeck SL, Wright MH, Varticovski L, Nagarajan M, Morrell A, Cushman M, Pommier Y.

Mol Pharmacol. 2006 Sep;70(3):1109-20. Epub 2006 Jun 23.

9.

Ligand-directed surface profiling of human cancer cells with combinatorial peptide libraries.

Kolonin MG, Bover L, Sun J, Zurita AJ, Do KA, Lahdenranta J, Cardó-Vila M, Giordano RJ, Jaalouk DE, Ozawa MG, Moya CA, Souza GR, Staquicini FI, Kunyiasu A, Scudiero DA, Holbeck SL, Sausville EA, Arap W, Pasqualini R.

Cancer Res. 2006 Jan 1;66(1):34-40.

10.

Correlation of PIK3Ca mutations with gene expression and drug sensitivity in NCI-60 cell lines.

Whyte DB, Holbeck SL.

Biochem Biophys Res Commun. 2006 Feb 10;340(2):469-75. Epub 2005 Dec 15.

PMID:
16376301
11.

HLA class I and II genotype of the NCI-60 cell lines.

Adams S, Robbins FM, Chen D, Wagage D, Holbeck SL, Morse HC 3rd, Stroncek D, Marincola FM.

J Transl Med. 2005 Mar 4;3(1):11.

12.

Transcription profiling of gene expression in drug discovery and development: the NCI experience.

Sausville EA, Holbeck SL.

Eur J Cancer. 2004 Nov;40(17):2544-9. Review.

PMID:
15541957
13.

In vitro evaluation of dimethane sulfonate analogues with potential alkylating activity and selective renal cell carcinoma cytotoxicity.

Mertins SD, Myers TG, Holbeck SL, Medina-Perez W, Wang E, Kohlhagen G, Pommier Y, Bates SE.

Mol Cancer Ther. 2004 Jul;3(7):849-60.

14.

Update on NCI in vitro drug screen utilities.

Holbeck SL.

Eur J Cancer. 2004 Apr;40(6):785-93.

PMID:
15120034
15.

Two CD95 tumor classes with different sensitivities to antitumor drugs.

Algeciras-Schimnich A, Pietras EM, Barnhart BC, Legembre P, Vijayan S, Holbeck SL, Peter ME.

Proc Natl Acad Sci U S A. 2003 Sep 30;100(20):11445-50. Epub 2003 Sep 22.

16.

COMPARE: a web accessible tool for investigating mechanisms of cell growth inhibition.

Zaharevitz DW, Holbeck SL, Bowerman C, Svetlik PA.

J Mol Graph Model. 2002 Jan;20(4):297-303.

PMID:
11858638
17.

Thymidylate synthase as a molecular target for drug discovery using the National Cancer Institute's Anticancer Drug Screen.

Parr AL, Myers TG, Holbeck SL, Loh YJ, Allegra CJ.

Anticancer Drugs. 2001 Aug;12(7):569-74.

PMID:
11487712
18.

EXO1 of Saccharomyces cerevisiae functions in mutagenesis during double-strand break repair.

Holbeck SL, Strathern JN.

Ann N Y Acad Sci. 1999 May 18;870:375-7. No abstract available.

PMID:
10415501
20.
21.

Chi enhances heteroduplex DNA levels during recombination.

Holbeck SL, Smith GR.

Genetics. 1992 Dec;132(4):879-91.

22.

Molecular analysis of DQ beta 3.1 genes.

Holbeck SL, Nepom GT.

Hum Immunol. 1988 Mar;21(3):183-92.

PMID:
2897347
23.

Specific allelic variation among linked HLA class II genes.

Amar A, Holbeck SL, Nepom GT.

Transplantation. 1987 Dec;44(6):831-5.

PMID:
2892292
24.

Characterization of specific HLA-DQ alpha allospecificities by genomic, biochemical, and serologic analysis.

Amar A, Radka SF, Holbeck SL, Kim SJ, Nepom BS, Nelson K, Nepom GT.

J Immunol. 1987 Jun 1;138(11):3986-90.

PMID:
2438332
25.

Identification of HLA-Dw14 genes in DR4+ rheumatoid arthritis.

Nepom GT, Seyfried CE, Holbeck SL, Wilske KR, Nepom BS.

Lancet. 1986 Nov 1;2(8514):1002-5.

PMID:
2877172
26.
27.

Exon-specific oligonucleotide probes localize HLA-DQ beta allelic polymorphisms.

Holbeck SL, Nepom GT.

Immunogenetics. 1986;24(4):251-8.

PMID:
2877944
28.

Identification of a polymorphic variant associated with HLA-DQw3 and characterized by specific restriction sites within the DQ beta-chain gene.

Kim SJ, Holbeck SL, Nisperos B, Hansen JA, Maeda H, Nepom GT.

Proc Natl Acad Sci U S A. 1985 Dec;82(23):8139-43.

29.

HLA-DR4-associated haplotypes are genotypically diverse within HLA.

Holbeck SL, Kim SJ, Silver J, Hansen JA, Nepom GT.

J Immunol. 1985 Jul;135(1):637-41.

PMID:
2987355
30.

Induction of immunity to a human tumor marker by in vivo administration of anti-idiotypic antibodies in mice.

Nepom GT, Nelson KA, Holbeck SL, Hellström I, Hellström KE.

Proc Natl Acad Sci U S A. 1984 May;81(9):2864-7.

31.

Enhanced Detection of immunoglobulin binding by a modified ELISA.

Holbeck SL, Nepom GT.

J Immunol Methods. 1983 May 27;60(1-2):47-52.

PMID:
6854031

Supplemental Content

Loading ...
Support Center